Payment overview · 2025
General Payments
$67.86
4 reported records · 3 companies
Healthcare provider profile · identity verified
Francesca Cerimele, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBERTVILLE, AL · NPI 1770591950
Verified facts
What the public records show
CMS Open Payments records show Francesca Cerimele, MD received $67.86 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.66 | 40.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.17 | 34.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.03 | 25.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $67.86 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.66 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 47 |
| Gabapentin | Gabapentin | 196 | 34 |
| Lisinopril | Lisinopril | 194 | 31 |
| Metformin Hcl | Metformin Hcl | 166 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 16 |
| Omeprazole | Omeprazole | 117 | 30 |
| Pregabalin | Pregabalin | 117 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 101 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 18 |
| Ozempic | Semaglutide | 84 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 13 |
| Losartan Potassium | Losartan Potassium | 76 | 16 |
| Meloxicam | Meloxicam | 75 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 15 |
| Azithromycin | Azithromycin | 69 | 39 |
| Jardiance | Empagliflozin | 69 | suppressed |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 64 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 24 |
| Celecoxib | Celecoxib | 57 | suppressed |
| Furosemide | Furosemide | 57 | 21 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 23 |
| Trazodone Hcl | Trazodone Hcl | 51 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 11 |
| Cefdinir | Cefdinir | 42 | 30 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Simvastatin | Simvastatin | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Prednisone | Prednisone | 33 | 19 |
| Temazepam | Temazepam | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 13 |
| Linzess | Linaclotide | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 21 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 15 |
| Finasteride | Finasteride | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 15 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Glipizide | Glipizide | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 15 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Diazepam | Diazepam | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $67.86 · 4 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA, QULIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error